Antidote Technologies, phaware Team Up to Recruit More Patients for Clinical Trials

Antidote Technologies, phaware Team Up to Recruit More Patients for Clinical Trials

Antidote Technologies, a digital health company, and phaware global association, an organization advocating for pulmonary hypertension (PH) awareness, will join forces to create a new recruitment system for pharmaceutical companies and contract research organizations (CROs) to enroll patients with chronic lung diseases in their clinical trials.

The partnership will bring together phaware’s proven patient engagement model and Antidote’s expertise on recruitment for clinical trials, to improve the recruitment efficiency of patients with PH and related diseases.

Marie Rand, co-founder and managing director of phaware, realized the importance of patients’ participation in research when she lost her daughter, Chloë, to PH. Before Chloë passed, she was part of a pioneering PH clinical trial for a medication that was approved in 1995.

“We need to get patients into trials today to improve their lives, as well as the lives of patients in the future,” Rand said in a press release. “We’re excited to partner with Antidote to bring our patients through the enrollment funnel so that they can contribute to innovations that will someday change the face of PH.”

Interested in PH research? Check out our forums and join the conversation!

This collaboration will give researchers access to patients with PH and related disorders via phaware’s community of patients and caregivers, and also to highly efficient disease screening via Antidote’s customized pre-screeners, advanced eligibility matching technology, and phone validation service.

Antidote will be in charge of managing the site through which patients should be effectively enrolled, as well as evaluating the patients’ recruitment plan based on the company’s enrollment tools.

There are currently more than 90 PH trials enrolling patients in the U.S., needing more than 21,000 patients. Estimates show that a total of 30,000 patients are diagnosed with PH in the U.S., meaning that 70 percent of these patients could participate in trials to accelerate research.

Patients’ recruitment for trials on rare diseases is a challenging task for both researchers and patients, with the former wanting to stay on time and on budget, and the latter seeking new and better treatments.

In the U.S., nearly 80 percent of clinical trials are delayed or closed because of difficulties in finding eligible patients to take part. More efficient recruitment strategies are key solutions for this issue.

“At Antidote, our mission is to connect patients to research through partnerships like the one we have forged with phaware,” said Tom Krohn, chief development officer at Antidote. “The community that phaware has built is inspiring, and we are honored to help these patients take part in potential breakthrough research opportunities.”

One comment

  1. Betsie Miklos says:

    I have 2 comments. 1) PH is not a rare disease – PAH is. It is important to be clear which you are really referencing. This definitely changes the size of your pool of participants.
    2) If a person is somewhere on PHAWARE’s “list” (FB, web site, etc) will their info be passed to Antidote without their permission?

Leave a Comment

Your email address will not be published. Required fields are marked *